{
    "id": "dbpedia_8100_2",
    "rank": 31,
    "data": {
        "url": "https://www.bioworld.com/keywords/28181-simcere-pharmaceutical-group-ltd",
        "read_more_link": "",
        "language": "en",
        "title": "Simcere Pharmaceutical Group Ltd.",
        "top_image": "https://www.bioworld.com/icons/favicon-32x32.png",
        "meta_img": "https://www.bioworld.com/icons/favicon-32x32.png",
        "images": [
            "https://www.bioworld.com/images/Cortellis_Flagship_Logo.png",
            "https://www.bioworld.com/ext/resources/BWS/BWS-library/University-of-Miami-Multiple-Myeloma.png?height=488&t=1672934489&width=650",
            "https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/TME-tumor-microenvironment-3D.jpg?height=488&t=1699370810&width=650",
            "https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Handshake_global2.png?height=488&t=1588276797&width=650",
            "https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Handshake_global2.png?height=488&t=1588276797&width=650",
            "https://www.bioworld.com/ext/resources/BWS/BWS-library/Antibody-binding-receptors.png?height=488&t=1672415568&width=650",
            "https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Eye-with-digital-overlay.jpg?height=355&t=1717017591&width=640",
            "https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Musculoskeletal/Girl-in-wheelchair.png?height=355&t=1617737781&width=640",
            "https://www.bioworld.com/ext/resources/BMT-source/2022/05-31-Abbott-FreeStyle-Libre-3-Sensor-Smartphone.png?height=355&t=1654033980&width=640",
            "https://www.bioworld.com/ext/resources/Ads/2024/BioFuture-2024-banner-300x250.png"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            "Simcere Pharmaceutical Group Ltd."
        ],
        "tags": null,
        "authors": [],
        "publish_date": null,
        "summary": "",
        "meta_description": "BioWorld Content on 'Simcere Pharmaceutical Group Ltd.'",
        "meta_lang": "en",
        "meta_favicon": "/icons/apple-touch-icon.png",
        "meta_site_name": "",
        "canonical_link": "https://www.bioworld.com/keywords/28181-simcere-pharmaceutical-group-ltd",
        "text": "Immuno-oncology\n\nTrispecific antibody SIM-0500 approved for trials in the US and China for multiple myeloma\n\nSimcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd., has received approval from the FDA and China’s National Medical Products Administration (NMPA) to conduct clinical trials with SIM-0500 in patients with relapsed or refractory multiple myeloma.\n\nRead More\n\nCancer\n\nSimcere’s USP1 inhibitor receives FDA clearance for clinical trials in solid tumors\n\nSimcere Pharmaceutical Group Ltd.’s subsidiary Simcere Zaiming Pharmaceutical Co. Ltd. has received FDA clearance of an IND application for SIM-0501, an oral small-molecule inhibitor of ubiquitin-specific peptidase 1 (USP1), for advanced solid tumors.\n\nRead More\n\nSimcere licenses China rights to Connect’s rademikibart in $120M deal\n\nConnect Biopharma Holdings Ltd. has been seeking a partner for its atopic dermatitis candidate rademikibart, and it appears to have found the perfect partner in Simcere Pharmaceutical Group, which gains exclusive rights to develop, manufacture and commercialize rademikibart in China in a deal worth $120 million plus royalties.\n\nRead More\n\nSimcere licenses China rights to Connect’s rademikibart in $120M deal\n\nConnect Biopharma Holdings Ltd. has been seeking a partner for its atopic dermatitis candidate rademikibart, and it appears to have found the perfect partner in Simcere Pharmaceutical Group, which gains exclusive rights to develop, manufacture and commercialize rademikibart in China in a deal worth $120 million plus royalties.\n\nRead More\n\nChina approves two oral drugs to treat COVID-19\n\nChina’s NMPA granted conditional approvals to two COVID-19 drugs under a special examination and approval procedure aimed at addressing urgent needs. The approvals are both for oral small-molecule drugs for adult patients with mild to moderate COVID-19 infections. One of the approved drugs is Simcere Pharmaceutical Group Ltd.’s Xiannuoxin (simnotrelvir/ritonavir). The other is Shanghai Junshi Biosciences Co. Ltd.’s VV-116 (deuremidevir hydrobromide).\n\nRead More\n\nChina approves two oral drugs to treat COVID-19\n\nChina’s NMPA granted conditional approvals to two COVID-19 drugs under a special examination and approval procedure aimed at addressing urgent needs. The approvals are both for oral small-molecule drugs for adult patients with mild to moderate COVID-19 infections. One of the approved drugs is Simcere Pharmaceutical Group Ltd.’s Xiannuoxin (simnotrelvir/ritonavir). The other is Shanghai Junshi Biosciences Co. Ltd.’s VV-116 (deuremidevir hydrobromide).\n\nRead More\n\nSimcere gets China rights for Idorsia’s daridorexant in $50M deal\n\nSimcere Pharmaceutical Group Ltd. has inked a licensing agreement picking rights to develop Idorsia Ltd.’s insomnia treatment in greater China, in exchange for a $30 million up-front payment.\n\nRead More"
    }
}